Transcriptomic data from patients with Still’s disease suggest decreased expression of the mTORC1 inhibitors TSC1/TSC2 and an mTORC1 gene signature that strongly correlates with disease activity and treatment response. The gene discussed is TSC2; the disease is systemic-onset juvenile idiopathic arthritis.